Cargando…

Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides

Gapmer antisense oligonucleotides cleave target RNA effectively in vivo, and is considered as promising therapeutics. Especially, gapmers modified with locked nucleic acid (LNA) shows potent knockdown activity; however, they also cause hepatotoxic side effects. For developing safe and effective gapm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kasuya, Takeshi, Hori, Shin-ichiro, Watanabe, Ayahisa, Nakajima, Mado, Gahara, Yoshinari, Rokushima, Masatomo, Yanagimoto, Toru, Kugimiya, Akira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961955/ https://www.ncbi.nlm.nih.gov/pubmed/27461380 http://dx.doi.org/10.1038/srep30377

Ejemplares similares

Identification of nucleobase chemical modifications that reduce the hepatotoxicity of gapmer antisense oligonucleotides
por: Yoshida, Tokuyuki, et al.
Publicado: (2022)

Sequence motifs associated with hepatotoxicity of locked nucleic acid—modified antisense oligonucleotides
por: Burdick, Andrew D., et al.
Publicado: (2014)

Effects of combinations of gapmer antisense oligonucleotides on the target reduction
por: Yanagidaira, Mitsugu, et al.
Publicado: (2023)

Reduction of Off-Target Effects of Gapmer Antisense Oligonucleotides by Oligonucleotide Extension
por: Yasuhara, Hidenori, et al.
Publicado: (2022)

Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals
por: Swayze, Eric E., et al.
Publicado: (2007)

Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides
por: Anderson, Brooke A, et al.
Publicado: (2021)

Evaluation of off‐target effects of gapmer antisense oligonucleotides using human cells
por: Yoshida, Tokuyuki, et al.
Publicado: (2019)

Fluorescent base analogues in gapmers enable stealth labeling of antisense oligonucleotide therapeutics
por: Nilsson, Jesper R., et al.
Publicado: (2021)

A cytoplasmic pathway for gapmer antisense oligonucleotide-mediated gene silencing in mammalian cells
por: Castanotto, Daniela, et al.
Publicado: (2015)

Likelihood of Nonspecific Activity of Gapmer Antisense Oligonucleotides Is Associated with Relative Hybridization Free Energy
por: Watt, Andrew T., et al.
Publicado: (2020)

Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts
por: Burel, Sebastien A., et al.
Publicado: (2016)

Structure Activity Relationships of α-L-LNA Modified Phosphorothioate Gapmer Antisense Oligonucleotides in Animals
por: Seth, Punit P, et al.
Publicado: (2012)

Bolaamphiphile-based nanocomplex delivery of phosphorothioate gapmer antisense oligonucleotides as a treatment for Clostridium difficile
por: Hegarty, John P, et al.
Publicado: (2016)

Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides
por: Østergaard, Michael E, et al.
Publicado: (2020)

Antiviral Efficacy of RNase H-Dependent Gapmer Antisense Oligonucleotides against Japanese Encephalitis Virus
por: Okamoto, Shunsuke, et al.
Publicado: (2023)

A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer
por: Shimojo, Masahito, et al.
Publicado: (2019)

Intratracheally administered LNA gapmer antisense oligonucleotides induce robust gene silencing in mouse lung fibroblasts
por: Shin, Minwook, et al.
Publicado: (2022)

Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents
por: Stein, C. A., et al.
Publicado: (2010)

Targeting murine alveolar macrophages by the intratracheal administration of locked nucleic acid containing antisense oligonucleotides
por: Uemura, Yasunori, et al.
Publicado: (2019)

Synthesis and biophysical properties of carbamate-locked nucleic acid (LNA) oligonucleotides with potential antisense applications
por: Thorpe, Cameron, et al.
Publicado: (2019)

Chemical Diversity of Locked Nucleic Acid-Modified Antisense Oligonucleotides Allows Optimization of Pharmaceutical Properties
por: Papargyri, Natalia, et al.
Publicado: (2019)

Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies
por: Easton, Amy, et al.
Publicado: (2022)

Alpha-l-Locked Nucleic Acid-Modified Antisense Oligonucleotides Induce Efficient Splice Modulation In Vitro
por: Raguraman, Prithi, et al.
Publicado: (2020)

Gapmer Antisense Oligonucleotides Suppress the Mutant Allele of COL6A3 and Restore Functional Protein in Ullrich Muscular Dystrophy
por: Marrosu, Elena, et al.
Publicado: (2017)

Antisense oligonucleotide gapmers containing phosphoryl guanidine groups reverse MDR1-mediated multiple drug resistance of tumor cells
por: Kupryushkin, Maxim S., et al.
Publicado: (2021)

Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection
por: Zhang, Y, et al.
Publicado: (2011)

An Investigation into the Potential of Targeting Escherichia coli rne mRNA with Locked Nucleic Acid (LNA) Gapmers as an Antibacterial Strategy
por: Goddard, Layla R., et al.
Publicado: (2021)

Targeted amplicon sequencing of wastewater samples for detecting SARS-CoV-2 variants with high sensitivity and resolution
por: Kuroiwa, Miho, et al.
Publicado: (2023)

An antisense amido-bridged nucleic acid gapmer oligonucleotide targeting SRRM4 alters REST splicing and exhibits anti-tumor effects in small cell lung cancer and prostate cancer cells
por: Yoshida, Misa, et al.
Publicado: (2023)

Towards Zwitterionic Oligonucleotides with Improved Properties: the NAA/LNA‐Gapmer Approach
por: Wojtyniak, Melissa, et al.
Publicado: (2020)

A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo
por: Gupta, Nidhi, et al.
Publicado: (2010)

In vitro inhibition of porcine reproductive and respiratory syndrome virus replication by short antisense oligonucleotides with locked nucleic acid modification
por: Zhu, Lingyun, et al.
Publicado: (2018)

Locked Nucleic Acid Gapmers and Conjugates Potently Silence ADAM33, an Asthma-Associated Metalloprotease with Nuclear-Localized mRNA
por: Pendergraff, Hannah M., et al.
Publicado: (2017)

The intratracheal administration of locked nucleic acid containing antisense oligonucleotides induced gene silencing and an immune-stimulatory effect in the murine lung
por: Uemura, Yasunori, et al.
Publicado: (2017)

Rational Design of Short Locked Nucleic Acid-Modified 2′-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro
por: Le, Bao T., et al.
Publicado: (2017)

Acute hepatotoxicity of 2′ fluoro-modified 5–10–5 gapmer phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins
por: Shen, Wen, et al.
Publicado: (2018)

Antisense Oligonucleotide in LNA-Gapmer Design Targeting TGFBR2—A Key Single Gene Target for Safe and Effective Inhibition of TGFβ Signaling
por: Kuespert, Sabrina, et al.
Publicado: (2020)

Intramuscular Evaluation of Chimeric Locked Nucleic Acid/2′OMethyl-Modified Antisense Oligonucleotides for Targeted Exon 23 Skipping in Mdx Mice
por: Georgiadou, Michaella, et al.
Publicado: (2021)

Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates
por: Straarup, Ellen Marie, et al.
Publicado: (2010)

Hydrogel-Assisted Antisense LNA Gapmer Delivery for In Situ Gene Silencing in Spinal Cord Injury
por: Moreno, Pedro M.D., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jgsje67pcig5ka6093545muuot